ArticleJournal of advanced research2026
Activated hepatic stellate cell-derived exosomal miR-23a-3p promotes hepatocellular carcinogenesis by regulating DUSP5/ERK signaling.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionActivation of hepatic stellate cells (HSCs) is a core driver of liver fibrosis and may contribute to the evolution to hepatocellular carcinoma (HCC). Exosomes mediate intercellular signaling by transporting bioactive molecules, yet the role of activated HSC-derived exosomes in hepatocarcinogenesis remains unexplored.
objectivesThis study aims to investigate whether and how activated HSCs induce hepatocarcinogenesis through the mediation of exosomes.
methodsExosomes from activated HSCs were isolated and applied to hepatocytes to assess malignant transformation via immunoblotting, soft-agar colony formation, and xenograft assays. Oncogenic miRNAs were screened by sequencing and validated by qPCR. Target genes and signaling pathways were identified through transcriptomics, bioinformatics, and dual-luciferase assays. Functional roles of miRNAs and downstream pathways were confirmed via gain/loss-of-function experiments. Clinical correlations and diagnostic potential of exosomal miRNAs were evaluated using patient samples.
resultsExosomes from activated HSCs induced hepatocyte malignant transformation in vitro and tumorigenesis in vivo. MiR-23a-3p was markedly enriched in activated HSC-derived exosomes and exerted oncogenic effect upon delivery to recipient hepatocytes. Mechanistically, exosomal miR-23a-3p directly targeted DUSP5 in hepatocytes, thereby suppressing its expression and subsequently activating pro-oncogenic ERK signaling. Notably, the miR-23a-3p/DUSP5/ERK signaling axis exhibited progressive activation that paralleled histopathological transitions from fibrosis to HCC in both murine models and clinical specimens. Clinically, elevated plasma exosomal miR-23a-3p levels demonstrated significant diagnostic merit for detecting precancerous lesions and predicting HCC onset in patient cohorts.
conclusionOur results indicate that activated HSCs secrete exosomes enriched with miR-23a-3p, which directly target to inhibit DUSP5, and subsequently activate ERK signaling in hepatocytes, leading to the initiation of cellular malignant transformation and tumorigenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.